Implications of the Australian guidelines for the United States.
作者信息
Freund D A, Evans D, Henry D, Dittus R
机构信息
Indiana University's School of Public and Environmental Affairs.
出版信息
Health Aff (Millwood). 1992 Winter;11(4):202-6. doi: 10.1377/hlthaff.11.4.202.
PMID:1483641
Abstract
摘要
相似文献
1
Implications of the Australian guidelines for the United States.
Health Aff (Millwood). 1992 Winter;11(4):202-6. doi: 10.1377/hlthaff.11.4.202.
2
Basing prescription drug payment on economic analysis: the case of Australia.
Health Aff (Millwood). 1992 Winter;11(4):191-6. doi: 10.1377/hlthaff.11.4.191.
3
Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?
Health Econ. 1992 Jul;1(2):85-92. doi: 10.1002/hec.4730010202.
4
Issues in mandatory economic assessment of pharmaceuticals.
Health Aff (Millwood). 1992 Winter;11(4):197-201. doi: 10.1377/hlthaff.11.4.197.
5
How well does your PBM perform?
Bus Health. 1999 Jan;17(1):24-9.
6
The need for health care reform.
Health Syst Rev. 1994 May-Jun;27(3):5-6.
7
Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
Aust Health Rev. 2001;24(2):21-4. doi: 10.1071/ah010021.
8
Congress has its brain on drug benefits.
Fortune. 2003 Jan 20;147(1):178.
9
Regulating manufacturer-affiliated communication in the information age.
Clin Pharmacol Ther. 1999 Jun;65(6):593-7. doi: 10.1016/S0009-9236(99)90080-2.
10
Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
Aust Health Rev. 2001;24(2):7-14. doi: 10.1071/ah010007.
引用本文的文献
1
The emerging government requirement for economic evaluation of pharmaceuticals.
Pharmacoeconomics. 1994;6 Suppl 1:42-50. doi: 10.2165/00019053-199400061-00012.
Zotero 插件